A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
← catalyst calendarNCT06468228 · readout ≤ 134 d
Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
1,400actual
Sites
279
Countries
Argentina, Australia, Austria +41
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-06-27 | actual | When the study began enrolling |
| Primary completion | Dec 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2024-06-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hidradenitis Suppurativa
Interventions
- Drug: Lutikizumab — also filed as ABT-981
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFPercentage of Participants Achieving Hidradenitis Suppurative Clinical Response (HiSCR) 75
measured At Week 16
Number of Participants with Adverse Events (AEs)
measured Up to Approximately Week 62
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed